1. Home
  2. LXEO vs NKTR Comparison

LXEO vs NKTR Comparison

Compare LXEO & NKTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LXEO
  • NKTR
  • Stock Information
  • Founded
  • LXEO 2017
  • NKTR 1990
  • Country
  • LXEO United States
  • NKTR United States
  • Employees
  • LXEO N/A
  • NKTR N/A
  • Industry
  • LXEO
  • NKTR Biotechnology: Pharmaceutical Preparations
  • Sector
  • LXEO
  • NKTR Health Care
  • Exchange
  • LXEO Nasdaq
  • NKTR Nasdaq
  • Market Cap
  • LXEO 140.6M
  • NKTR 160.4M
  • IPO Year
  • LXEO 2023
  • NKTR 1994
  • Fundamental
  • Price
  • LXEO $4.10
  • NKTR $0.74
  • Analyst Decision
  • LXEO Strong Buy
  • NKTR Strong Buy
  • Analyst Count
  • LXEO 5
  • NKTR 5
  • Target Price
  • LXEO $22.80
  • NKTR $5.50
  • AVG Volume (30 Days)
  • LXEO 919.4K
  • NKTR 1.4M
  • Earning Date
  • LXEO 03-24-2025
  • NKTR 03-12-2025
  • Dividend Yield
  • LXEO N/A
  • NKTR N/A
  • EPS Growth
  • LXEO N/A
  • NKTR N/A
  • EPS
  • LXEO N/A
  • NKTR N/A
  • Revenue
  • LXEO N/A
  • NKTR $98,427,000.00
  • Revenue This Year
  • LXEO N/A
  • NKTR N/A
  • Revenue Next Year
  • LXEO N/A
  • NKTR N/A
  • P/E Ratio
  • LXEO N/A
  • NKTR N/A
  • Revenue Growth
  • LXEO N/A
  • NKTR 9.21
  • 52 Week Low
  • LXEO $2.32
  • NKTR $0.65
  • 52 Week High
  • LXEO $19.50
  • NKTR $1.93
  • Technical
  • Relative Strength Index (RSI)
  • LXEO 57.61
  • NKTR 36.32
  • Support Level
  • LXEO $3.75
  • NKTR $0.84
  • Resistance Level
  • LXEO $4.59
  • NKTR $0.92
  • Average True Range (ATR)
  • LXEO 0.48
  • NKTR 0.08
  • MACD
  • LXEO 0.24
  • NKTR -0.01
  • Stochastic Oscillator
  • LXEO 76.89
  • NKTR 0.40

About LXEO Lexeo Therapeutics Inc.

Lexeo Therapeutics Inc is a a clinical-stage genetic medicines company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated. Its pipeline consists of candidates targeting patient populations that place significant burden on society and are most amenable to their genetic medicine approach. The Company is focused on preclinical and clinical stage gene therapies, and specifically on hereditary and acquired diseases of high unmet need which is their only business segment.

About NKTR Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, The company is focused on activating the immune system natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.

Share on Social Networks: